



**PROTECH**

**Factsheet**

  
**Spain**

**Men who  
have sex  
with men**

# **Inject PrEP to protect?**

The first Pan European study exploring the willingness to use long-acting injectable PrEP to prevent HIV.



**Maastricht University**

# What is the PROTECT Survey?

This online survey was conducted across Europe (Oct 2023 to March 2024) and sought to uncover who may benefit from the innovation that is long-acting injectable PrEP.


The European Commission (EC) has authorized Apretude ® (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention.

It is important for health services and policy makers to understand who may be interested in taking long-acting injectable PrEP so that resources can be most effectively allocated.


**This factsheet reports on data from the PROTECT Survey collected in Spain from men who have sex with men N=1985.**



SEXUAL ORIENTATION




AGE






### MIGRANT STATUS



- First Generation migrant: 552
- Local population: 1331
- Second Generation migrant: 102

### RELATIONSHIP STATUS




- Single, not dating: 222
- Single, dating: 1052
- In a relationship: 291
- In an open/polyamorous relationship: 420






CHEMSEX (in the past 6 months)



NUMBER OF SEXUAL PARTNERS (in the past 6 months)






Example of campaign image




HIV TESTING FREQUENCY



- More than every 6 months: 692
- Every 6 months: 444
- Less than once a year: 243
- Once a year: 462
- Never: 144


ORAL PrEP USE HISTORY & CURRENT PrEP REGIMEN

Naive: 1252 Current: 599 Former: 134






**AWARENESS OF ORAL PrEP**



**CURRENT PrEP USERS – ACCESS TO ORAL PrEP**



# Barriers to oral PrEP use

- **13% of the MSM said:**
  - Oral PrEP was too costly (either the pills or the tests associated with PrEP use)
- **24% of the MSM said:**
  - The procedure took too long to obtain oral PrEP when they needed it
- **34% of the MSM said:**
  - Their healthcare provider did not offer oral PrEP to them
- **26% of the MSM said:**
  - There was a waiting list at their healthcare provider for oral PrEP and the service was not available






# Long-acting PrEP: interest and intention

**79%**

are interested in using LA-PrEP if it becomes available.

**80%**

intend to use LA-PrEP if it becomes available.



# What LA-PrEP could mean to participants

This word cloud was generated from responses that participants provided to a question asking them what LA-PrEP could mean to them, if it were to become available.



# Summary & Contact Information

## SUMMARY

- Spanish MSM are aware of PrEP and have taken up oral PrEP
- Barriers to starting PrEP still exist
- Interest and intention to use LA-PrEP among MSM in Spain is high
- LA-PrEP may provide an opportunity for greater HIV prevention in Spain

## CONTACT INFORMATION

- Prof. Dr. Kai J. Jonas  
Email: [kai.jonas@maastrichtuniversity.nl](mailto:kai.jonas@maastrichtuniversity.nl)
- Dr. Johann Kolstee  
Email:  
[johann.kolstee@maastrichtuniversity.nl](mailto:johann.kolstee@maastrichtuniversity.nl)
- Maastricht University postal address  
P.O. Box 616, 6200 MD Maastricht, The Netherlands